EU committee approves SPC waiver
The Legal Committee of the European Parliament has voted in favour of the proposed supplementary protection certificate waiver.
Australian court allows application for cattle genome patent
The Federal Court of Australia has allowed an application for a cattle genome patent, following a legal battle.
EPO invalidates Pacific Biosciences patent in Oxford Nanopore dispute
The European Patent Office has revoked a patent held by a US biotechnology company, Pacific Biosciences, after its UK-based rival Oxford Nanopore Technologies challenged the validity of the patent.
South Korean global licensing spikes n 2018
South Korean pharmaceutical companies entered into 11 out-licensing deals with overseas partners in 2018, according to the country’s Ministry of Health and Welfare.
HGF adds IP partner in The Hague office
Law firm HGF has added Leythem Wall as a partner.
PTAB denies Novartis petitions to review Plexxikon patents
The US Patent and Trademark Office has declined to hear two petitions filed by Switzerland-based Novartis to review two patents owned by drug discovery company Plexxikon.
Novartis enters AI partnership with Oxford University
Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.
Cannabis companies sign licensing deal on edible product
Canadian cannabis manufacturing company, Chemesis International, has signed an agreement with GSRX Industries, a Puerto-Rico based dispensary, to manufacture an edible cannabis product on the island.
PTAB issues final decision in CBD patent dispute
US-based Insys Therapeutics has succeeded in its bid to prove that two of the claims in a patent owned by British company GW Pharmaceuticals were covered by a prior invention.
Life sciences lawyers shocked and concerned amid Brexit uncertainty
Lawyers have told LSIPR they are concerned about the continuing UK political uncertainty having a negative impact on life sciences investment and the Unified Patent Court.
